Business Description
Description
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.41 | |||||
| Beneish M-Score | 13.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -58.6 | |||||
| 3-Year EBITDA Growth Rate | -60.7 | |||||
| 3-Year EPS without NRI Growth Rate | -66.1 | |||||
| 3-Year FCF Growth Rate | -49.4 | |||||
| 3-Year Book Growth Rate | -18.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 30.92 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.54 | |||||
| 9-Day RSI | 47.11 | |||||
| 14-Day RSI | 43.88 | |||||
| 6-1 Month Momentum % | 13.4 | |||||
| 12-1 Month Momentum % | -79.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | |||||
| Quick Ratio | 2.16 | |||||
| Cash Ratio | 0.74 | |||||
| Days Inventory | 375.96 | |||||
| Days Sales Outstanding | 287.42 | |||||
| Days Payable | 481.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.62 | |||||
| Operating Margin % | -783.09 | |||||
| Net Margin % | -776.64 | |||||
| ROE % | -57.38 | |||||
| ROA % | -53.91 | |||||
| ROIC % | -81.87 | |||||
| ROC (Joel Greenblatt) % | -957.46 | |||||
| ROCE % | -56.36 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.04 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 2.18 | |||||
| EV-to-EBIT | -1.54 | |||||
| EV-to-Forward-EBIT | -1.61 | |||||
| EV-to-EBITDA | -1.68 | |||||
| EV-to-Forward-EBITDA | -2.59 | |||||
| EV-to-Revenue | 11.72 | |||||
| EV-to-Forward-Revenue | 1.39 | |||||
| EV-to-FCF | -1.73 | |||||
| Price-to-Net-Current-Asset-Value | 3.28 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | -64.94 |
